An Overview of Our Pipeline
Eos SENOLYTIX
| PRODUCT CANDIDATES | PRE-CLINICAL | PHASE 1 | PHASE 2/3 |
|---|---|---|---|
| Program Area: Systemic Rejuvenation and Longevity | |||
| MitoXcel™ Geropeptides | |||
| PTC-2105 (Mechanism 1 and 2) LEAD CLINICAL CANDIDATE |
Sarcopenia and Sarcopenic Obesity
|
||
| PTC-2107 (Mechanism 1 and 2) |
Neurodegenerative Disorders, e.g. ALZ, PD
Cognitive Decline of Aging
|
||
| PTC-2113 (Mechanism 1) |
Obesity and Glucose Metabolic Disorders
|
||
| PTC-2118 (Mechanism 1 and 2) |
Mitochondrial Rare Diseases
|
||
Perseus SENOLYTIX
| PRODUCT CANDIDATES | PRE-CLINICAL | PHASE 1 | PHASE 2/3 |
|---|---|---|---|
| Program Area: MitoXcel Oncopeptides Targeting the Mitochondrial Δψm | |||
| MitoXcel™ Oncopeptides | |||
| PTC-2128 (lead clinical indication) |
Melanoma
|
||
| PTC-2128 |
Breast Cancer
|
||
| PTC-2109 PTC-2110 |
Ph+ B-ALL, Ph-“like” B-ALL, Burkitt’s lymphoma, T-ALL, and AML
|
||
| PTC-2110 |
Prevention of Radiation Toxicity
|
||
| Program Area: DEL-Discovered Tyrosine Kinases | |||
| Novel Tyrosine Kinases | |||
| DTC-0657/0571 |
CML, Ph+ ALL and Ph+ “Like” ALL
|
||
| DTC-0282/0367/0372 |
Solid Tumors (colon, bladder, liver, etc.)
|
||
| DTC-0531/0552 |
ROS1 L2086F Mutations (lung)
|
||
Ponce Aurora
PTC-2111, PTC-2119 and PTC-2132 have never been tested in animals.
| PRODUCT CANDIDATES | PRE-COMMERCIAL | COMMERCIAL |
|---|---|---|
| Program Area: MitoXcel™ Geropeptides – Topical and Oral | ||
| MitoXcel™ Technology | ||
| PTC-2111 (Mechanism 1 and 2) (NEVER TESTED IN ANIMALS) |
Topical
|
|
| PTC-2119 (Mechanism 1 and 2) (NEVER TESTED IN ANIMALS) |
Topical
|
|
| PTC-2116 (Mechanism 1) |
Oral
|
|
| PTC-2132 (Mechanism 1 and 2) (NEVER TESTED IN ANIMALS) |
Oral
|
|
